Condition: Age-Related Macular Degeneration · Sponsor: Benobio Co., Ltd.
This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.
This description comes directly from the study's public registry record.
jihye choe · +827046675278 · jihye.choe@benobio.com
Always discuss trial participation with your own doctor first.
| Benobio Investigational site | Sydney, New South Wales, Australia | Not Yet Recruiting |
| Sydney Hospital | Sydney, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05803785